-
Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE
•
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and US-based Intuitive Surgical Inc., has announced the official launch of the Da Vinci Xi surgical robot at the 6th China International Import Expo (CIIE) in Shanghai. The Da Vinci Xi…
-
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
•
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based Biotheus Inc., focusing on the development and commercialization of the bispecific antibody (BsAb) PM8002. The deal grants BioNTech development, manufacturing, and commercial rights to PM8002 in all markets outside of Greater China, marking a significant…
-
MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries
•
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial approvals for its novel anti-microbial agent MRX-4 in combination with contezolid (MRX-I) as a sequential treatment for diabetic foot infections. The approvals span several countries, including the United Kingdom, Turkey, Georgia, Argentina, and Chile. Both…
-
Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with AstraZeneca (AZ, NASDAQ: AZN), securing exclusive retail distribution rights for the renowned digestive drug Losec (omeprazole) in mainland China. The financial details of this agreement have not been disclosed. This partnership follows Baheal’s previous acquisition…
-
Ji Xing Pharmaceuticals Partners with WuXi STA for Sterile Nasal Spray Production
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a strategic partnership with WuXi STA, a subsidiary of WuXi AppTec (HKG: 2359, SHA: 603259), to establish a sterile nasal spray production line. This collaboration aims to leverage the strengths of both companies, with the new production facility set to…
-
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
•
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing on the clinical characteristics and treatment patterns associated with its mineralocorticoid receptor antagonist (MRA), Kerendia (finerenone). This medication has received global approvals aimed at reducing cardiorenal risk in patients suffering from chronic kidney disease (CKD)…
-
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
•
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has released the results of a Phase II study combining its antibody drug conjugate (ADC) Adcetris (brentuximab vedotin) with Merck, Sharp & Dohme’s (MSD; NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab). The study focused on patients with…
-
AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of ETA receptor antagonist zibotentan and SGLT2 inhibitor dapagliflozin achieved dose-dependent reductions in urinary albumin-to-creatinine ratio (UACR) during a Phase IIb trial for chronic kidney disease (CKD). This development marks a significant step forward in the…
